Treatment of Multisystem Inflammatory Syndrome in Children

Area of Science:

• Pediatric critical care
• Infectious diseases
• Immunology

Background:

• Multisystem inflammatory syndrome in children (MIS-C) is a serious condition linked to SARS-CoV-2.
• Urgent evidence is needed to guide treatment decisions for pediatric MIS-C.
• Current treatment strategies lack definitive comparative data.

Purpose of the Study:

• To compare the effectiveness of different primary immunomodulatory treatments for MIS-C.
• To evaluate intravenous immune globulin (IVIG) alone versus IVIG plus glucocorticoids and glucocorticoids alone.
• To assess key clinical outcomes including need for support and disease severity reduction.

Main Methods:

• International observational cohort study of suspected MIS-C cases.
• Data collected via a web-based physician-reported database.
• Inverse-probability weighting and generalized linear models used for comparative analysis.

Main Results:

• 490 children meeting WHO criteria for MIS-C were analyzed from 614 suspected cases.
• No significant differences in the composite outcome of inotropic support, mechanical ventilation, or death were observed between treatment groups.
• Adjusted odds ratios for reduction in disease severity were similar across IVIG alone, IVIG plus glucocorticoids, and glucocorticoids alone groups.

Conclusions:

• Current data show no clear evidence of differential recovery based on primary treatment with IVIG alone, IVIG plus glucocorticoids, or glucocorticoids alone for MIS-C.
• The study highlights the need for continued data collection as potential differences may emerge with larger sample sizes.
• Findings support the ongoing evaluation of immunomodulatory therapies in pediatric critical care settings.